TDMS Study 93020-08 Pathology Tables
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
FINAL #1 MICE
Facility: Southern Research Institute
Chemical CAS #: 693-13-0
Lock Date: 03/14/03
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 5 5 6 4
Moribund Sacrifice 12 11 4 5
Accidently Killed 1 1 1
Survivors
Terminal Sacrifice 33 32 38 40
Natural Death 1
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (49) (50)
Gallbladder (42) (47) (42) (47)
Intestine Large, Colon (49) (48) (48) (48)
Intestine Large, Cecum (46) (45) (44) (47)
Intestine Small, Duodenum (46) (46) (44) (47)
Adenoma 1 (2%)
Intestine Small, Jejunum (47) (45) (44) (46)
Adenoma 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Intestine Small, Ileum (46) (44) (45) (47)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 8 (16%) 2 (4%) 7 (14%) 3 (6%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%)
Hepatocellular Adenoma 13 (26%) 16 (32%) 10 (20%) 9 (18%)
Hepatocellular Adenoma, Multiple 8 (16%) 11 (22%) 11 (22%) 9 (18%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%)
Liposarcoma, Metastatic, Tissue NOS 1 (2%)
Mesentery (23) (20) (14) (18)
Hemangiosarcoma, Metastatic, Liver 1 (6%)
Histiocytic Sarcoma 1 (4%) 2 (14%) 2 (11%)
Liposarcoma 1 (6%)
Pancreas (50) (48) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Salivary Glands (50) (50) (50) (49)
Page 2
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Forestomach (50) (49) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Stomach, Glandular (49) (48) (47) (50)
Tooth (1) (1) (1) (2)
Peridontal Tissue, Histiocytic Sarcoma,
Metastatic, Uncertain Primary Site 1 (100%)
Peridontal Tissue, Histiocytic Sarcoma,
Metastatic, Nose 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Medulla (49) (50) (49) (49)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (49) (50) (50)
Adenoma 2 (4%)
Pituitary Gland (48) (50) (50) (46)
Pars Distalis, Adenoma 4 (8%) 12 (24%) 3 (6%) 10 (22%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%) 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (5) (8) (3) (4)
Abdominal, Pelvic, Liposarcoma 1 (13%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (25%)
Page 3
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM - cont
Mediastinum, Histiocytic Sarcoma 1 (20%) 1 (33%)
Thoracic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (25%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (50) (49) (49)
Cystadenoma 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Teratoma Benign 1 (2%)
Oviduct (3) (1)
Uterus (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%) 2 (4%)
Leiomyosarcoma 2 (4%)
Endometrium, Carcinoma 1 (2%)
Endometrium, Polyp Stromal 4 (8%) 2 (4%) 5 (10%)
Endometrium, Sarcoma Stromal 1 (2%)
Vagina (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Liposarcoma, Metastatic, Tissue NOS 1 (2%)
Lymph Node (11) (13) (10) (10)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (10%)
Iliac, Carcinoma, Metastatic, Uterus 1 (8%)
Iliac, Histiocytic Sarcoma 1 (10%)
Mediastinal, Histiocytic Sarcoma 1 (9%) 1 (10%) 1 (10%)
Pancreatic, Histiocytic Sarcoma 1 (10%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (10%)
Renal, Histiocytic Sarcoma 1 (10%)
Lymph Node, Mandibular (47) (49) (49) (48)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Page 4
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mesenteric (47) (48) (49) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Spleen (49) (49) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 2 (4%)
Thymus (46) (48) (44) (47)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (49) (49)
Carcinoma 1 (2%) 2 (4%)
Skin (50) (50) (50) (50)
Basosquamous Tumor Benign 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Site of Application, Basal Cell Adenoma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangioma 2 (4%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Melanoma Malignant 1 (2%) 1 (2%)
Subcutaneous Tissue, Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Site of Application,
Melanoma Benign 1 (2%)
Subcutaneous Tissue, Site of Application,
Myxoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Cranium, Osteosarcoma 1 (2%)
Skeletal Muscle (4) (1) (1)
Lipoma 1 (25%)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Spinal Cord (1) (3) (2)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Liposarcoma, Metastatic, Tissue NOS 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Nose (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (47) (48) (49) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Retrobulbar, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Retrobulbar, Sarcoma 1 (2%)
Harderian Gland (50) (49) (50) (50)
Adenoma 9 (18%) 5 (10%) 5 (10%) 3 (6%)
Carcinoma 1 (2%) 4 (8%) 1 (2%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50) (49)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%)
Ureter (1) (1)
Histiocytic Sarcoma 1 (100%)
Urinary Bladder (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%) 2 (4%)
Lymphoma Malignant 10 (20%) 9 (18%) 7 (14%) 7 (14%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 43 41 41
Total Primary Neoplasms 85 84 76 70
Total Animals with Benign Neoplasms 35 38 28 31
Total Benign Neoplasms 52 62 44 44
Total Animals with Malignant Neoplasms 26 19 26 18
Total Malignant Neoplasms 33 22 32 26
Total Animals with Metastatic Neoplasms 3 3 9 4
Total Metastatic Neoplasm 4 5 11 7
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 1 2 5
Natural Death 6 9 10 8
Accidently Killed 1
Survivors
Terminal Sacrifice 38 40 38 36
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (46) (43) (44) (42)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (46) (44) (44) (40)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Intestine Small, Jejunum (46) (43) (44) (40)
Carcinoma 1 (2%) 1 (3%)
Intestine Small, Ileum (46) (44) (44) (40)
Carcinoma 1 (2%)
Liver (50) (50) (50) (49)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 16 (32%) 8 (16%) 8 (16%) 8 (16%)
Hepatocellular Carcinoma, Multiple 4 (8%) 7 (14%) 3 (6%) 3 (6%)
Hepatocellular Adenoma 9 (18%) 15 (30%) 11 (22%) 10 (20%)
Hepatocellular Adenoma, Multiple 9 (18%) 7 (14%) 8 (16%) 9 (18%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (49) (49) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Uncertain
Page 9
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Primary Site 1 (2%)
Pancreas (49) (50) (49) (49)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Duct, Carcinoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Serosa, Carcinoma, Metastatic, Pancreas 1 (2%)
Stomach, Glandular (50) (47) (48) (47)
Carcinoma, Metastatic, Pancreas 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (49)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Bilateral, Subcapsular, Adenoma 1 (2%)
Subcapsular, Adenoma 3 (6%) 2 (4%) 6 (12%) 4 (8%)
Adrenal Medulla (49) (50) (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (50) (49) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (48) (47) (50) (49)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (49) (49) (49) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma 1 (2%)
Tissue NOS (3) (2)
Abdominal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (33%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (33%) 1 (50%)
Thoracic, Hepatocellular Carcinoma,
Metastatic, Liver 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Prostate (50) (50) (50) (50)
Carcinoma 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Lymph Node (6) (5) (5) (4)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (25%)
Mediastinal, Hepatoblastoma, Metastatic,
Liver 1 (17%)
Mediastinal, Sarcoma, Metastatic, Uncertain
Primary Site 1 (25%)
Lymph Node, Mandibular (47) (48) (47) (47)
Lymph Node, Mesenteric (50) (48) (49) (48)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Spleen (49) (50) (50) (47)
Hemangiosarcoma 1 (2%) 2 (4%)
Thymus (47) (44) (47) (46)
Page 11
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (1) (1)
Carcinoma 1 (100%)
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hepatoblastoma,
Metastatic, Liver 1 (2%)
Subcutaneous Tissue, Site of Application,
Lymphoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (2) (2) (5)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (20%)
Carcinoma, Metastatic, Pancreas 1 (20%)
Hemangiosarcoma 1 (50%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (50%)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Peripheral Nerve (1) (1) (3)
Schwannoma Malignant 1 (33%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 5 (10%) 7 (14%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Page 12
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 6 (12%) 4 (8%) 3 (6%)
Hepatocellular Carcinoma, Metastatic, Lung 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%) 1 (2%)
Nose (49) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (46) (46) (47) (44)
Retrobulbar, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Retrobulbar, Sarcoma 1 (2%)
Harderian Gland (50) (50) (50) (50)
Adenoma 6 (12%) 9 (18%) 10 (20%) 8 (16%)
Carcinoma 2 (4%) 1 (2%) 3 (6%)
Bilateral, Adenoma 3 (6%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (48) (50) (48)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Uncertain
Primary Site 1 (2%)
Capsule, Carcinoma, Metastatic, Pancreas 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (50) (49) (50)
Hemangioma 1 (2%) 1 (2%)
Serosa, Hemangiosarcoma 1 (2%)
Page 13
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 14
NTP Experiment-Test: 93020-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIISOPROPYLCARBODIIMIDE Date: 07/19/04
Route: SKIN APPLICATION Time: 09:11:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 10 MG/KG 20 MG/KG 40 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 42 42 41
Total Primary Neoplasms 75 71 74 78
Total Animals with Benign Neoplasms 29 31 33 31
Total Benign Neoplasms 44 46 47 45
Total Animals with Malignant Neoplasms 27 21 22 23
Total Malignant Neoplasms 31 25 27 33
Total Animals with Metastatic Neoplasms 8 6 4 8
Total Metastatic Neoplasm 16 11 12 22
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 15
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------